Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07526545 · ClinicalTrials.gov registry record · NA
Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial
A NA study, sponsored by University of Michigan Rogel Cancer Center.
- Not yet
- Registry status
- NA
- Development phase
- 800
- Enrollment target
NCT07526545 is a NA study that has not yet begun recruiting, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 800 participants.
The verdict
NCT07526545, a NA study, has not yet begun recruiting, sponsored by University of Michigan Rogel Cancer Center.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 800 participants
- Enrollment target
Study Summary
This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likelihood of having aggressive prostate cancer. MPS2 testing works by measuring specific early detection biomarkers that include genetic information. This next-generation test aims to address a major challenge in prostate cancer care-detecting only the cancers that truly need treatment. Results may lead to paradigm shifts in early detection algorithms and reduce reliance on MRI and biopsy.
Interventions
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Biopsy Procedure
- OTHER Electronic Health Record Review
- DEVICE Diagnostic Procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2030-03-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07526545
The ClinicalTrials.gov registry entry for NCT07526545 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT07526545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07526545 about?
NCT07526545 is a clinical study titled "Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial". This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likelihood of having aggress...
What is the current status of trial NCT07526545?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 800 participants. The study started on 2026-09-01. Estimated completion is 2030-03-01.
What interventions are being tested in trial NCT07526545?
The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Biopsy Procedure (PROCEDURE), Electronic Health Record Review (OTHER), Diagnostic Procedure (DEVICE).
Who is sponsoring clinical trial NCT07526545?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.